DE3260474D1 - Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them - Google Patents

Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them

Info

Publication number
DE3260474D1
DE3260474D1 DE8282100490T DE3260474T DE3260474D1 DE 3260474 D1 DE3260474 D1 DE 3260474D1 DE 8282100490 T DE8282100490 T DE 8282100490T DE 3260474 T DE3260474 T DE 3260474T DE 3260474 D1 DE3260474 D1 DE 3260474D1
Authority
DE
Germany
Prior art keywords
aromatic heterocyclic
steroids
preparation
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8282100490T
Other languages
German (de)
English (en)
Inventor
Elliot L Shapiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE3260474D1 publication Critical patent/DE3260474D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
DE8282100490T 1981-02-02 1982-01-25 Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them Expired DE3260474D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23076381A 1981-02-02 1981-02-02

Publications (1)

Publication Number Publication Date
DE3260474D1 true DE3260474D1 (en) 1984-09-06

Family

ID=22866476

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8282100490T Expired DE3260474D1 (en) 1981-02-02 1982-01-25 Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them

Country Status (25)

Country Link
US (1) US4472393A (enExample)
EP (1) EP0057401B1 (enExample)
JP (1) JPS57146800A (enExample)
KR (1) KR890000761B1 (enExample)
AT (1) ATE8790T1 (enExample)
AU (1) AU549102B2 (enExample)
BG (1) BG60799B2 (enExample)
CA (1) CA1177822A (enExample)
CY (1) CY1359A (enExample)
DE (1) DE3260474D1 (enExample)
DK (1) DK162770C (enExample)
FI (1) FI78111C (enExample)
HK (1) HK68487A (enExample)
HU (1) HU188769B (enExample)
IE (1) IE52576B1 (enExample)
IL (1) IL64885A (enExample)
KE (1) KE3694A (enExample)
MX (1) MX9203403A (enExample)
NL (1) NL930095I2 (enExample)
NO (2) NO157020C (enExample)
NZ (1) NZ199600A (enExample)
OA (1) OA07116A (enExample)
PH (1) PH19733A (enExample)
PT (1) PT74357B (enExample)
ZA (1) ZA82566B (enExample)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446177A (en) * 1984-12-28 1995-08-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4914090A (en) * 1985-11-01 1990-04-03 Schering Corporation Ophthalmic compositions
IL79661A (en) * 1986-08-08 1991-01-31 Yeda Res & Dev Antiviral composition containing hypericin or pseudohypericin
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
MY105368A (en) * 1990-03-02 1994-09-30 Glaxo Group Ltd Inhalation device.
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
DE19875032I2 (de) 1990-09-10 2007-04-19 Schering Corp Mometason-Furoate-Monohydrat, Verfahren zu seiner Herstellung und das enthaltende pharmazeutische Zusammensetzungen
ATE339952T1 (de) 1991-06-10 2006-10-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
DK0656206T3 (da) † 1991-06-10 2001-10-08 Schering Corp Aerosolformuleringer uden chlorfluorcarbonforbindelser
US6127353A (en) * 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2221928T3 (es) * 1993-12-21 2005-01-16 Schering Corporation Pomadas que comprenden furoato de mometasona y acido salicilico para el tratamiento topico de la psoriasis.
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5502076A (en) * 1994-03-08 1996-03-26 Hoffmann-La Roche Inc. Dispersing agents for use with hydrofluoroalkane propellants
DE4433374A1 (de) * 1994-09-20 1996-03-21 Hoechst Ag 17-Desoxi-corticosteroid-21-/O/-Carbonsäure- ester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
PL185637B1 (pl) * 1996-06-28 2003-06-30 Schering Corp Sposób wytwarzania 17-estrów 9alfa, 21-dihalo-pregnano-11beta, 17alfa-diol-20-onów
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6297227B1 (en) 1998-09-10 2001-10-02 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
NZ500555A (en) * 1999-08-02 2000-11-24 Hovione Int Ltd Process for the preparation of mometasone furoate
PT102405A (pt) * 2000-01-20 2001-07-31 Hovione Farmaciencia Sa Processo para a preparacao de mometasona
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009609D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic compositions
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
AU7649701A (en) * 2000-08-05 2002-02-18 Glaxo Group Ltd 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CN1302007C (zh) * 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物
ES2307751T3 (es) * 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
GB0127160D0 (en) * 2001-11-12 2002-01-02 Glaxo Group Ltd Novel compounds
WO2003042229A1 (en) * 2001-11-12 2003-05-22 Glaxo Group Limited Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
US20050186144A1 (en) * 2004-01-21 2005-08-25 Schering Corporation Treatment methods
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
EP1948167A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions of phosphodiesterase type iv inhibitors
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
WO2008126076A2 (en) * 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
US20100240621A1 (en) * 2007-09-10 2010-09-23 Glenmark Pharmaceuticals Ltd. Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
US20090082318A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched mometasone
US8796248B2 (en) * 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
NZ589444A (en) 2008-05-28 2013-03-28 Validus Biopharma Inc NON-HORMONAL STEROID MODULATORS OF NF-Kappa B FOR TREATMENT OF DISEASE
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
HUE029532T2 (en) * 2009-05-29 2017-03-28 Pearl Therapeutics Inc Respiratory delivery of active agents
HRP20181266T1 (hr) 2009-10-01 2018-10-05 Adare Pharmaceuticals, Inc. Kortikosteroidni pripravci za oralnu primjenu
WO2011093810A2 (en) 2010-01-28 2011-08-04 Bilgic Mahmut Dry powder pharmaceutical composition comprising tiotropium and mometasone
EP2533765A2 (en) 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
EP2556083A4 (en) 2010-04-05 2013-12-04 Validus Biopharma Inc NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT
WO2011136754A1 (en) 2010-04-26 2011-11-03 Mahmut Bilgic A medicament developed for the treatment of respiratory diseases
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
WO2013109207A1 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising mometasone
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
US20150224197A1 (en) 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
JP6232079B2 (ja) 2013-03-14 2017-11-15 ノバルティス アーゲー スプレーブレンディングによるスプレー乾燥製剤の脱アモルファス化
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
HK1221654A1 (zh) 2013-05-22 2017-06-09 珍珠治疗公司 用於呼吸递送三种或更多种活性剂的组合物、方法和系统
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
MX2016012641A (es) 2014-03-27 2016-12-14 Novartis Ag Dispersiones solidas secas en aceite en agua por aspersion para inhalacion de ingredientes farmaceuticos activos.
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
CN105481933B (zh) * 2015-12-25 2017-09-19 山东京卫制药有限公司 一种合成糠酸莫米松的方法
CN107266519B (zh) * 2016-04-08 2021-06-29 天津金耀集团有限公司 一种9β，11β-环氧-17α-羟基-16α-甲基-21-氯代-1，4孕甾二烯-3，20-二酮新晶型及其制备方法
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN107778341A (zh) * 2016-08-30 2018-03-09 天津太平洋制药有限公司 一种哈西奈德的制备方法
CN107793462A (zh) * 2016-08-30 2018-03-13 天津太平洋制药有限公司 一种丙酸氯倍他索的制备方法
CN109206468B (zh) * 2017-06-30 2023-06-27 天津药业研究院股份有限公司 一种糠酸莫米松的制备方法
CN109206466B (zh) * 2017-06-30 2022-08-09 天津药业研究院股份有限公司 一种甾体21位羟基氯代或溴代方法
CN107573398B (zh) * 2017-09-07 2021-02-26 山东泰华生物科技股份有限公司 一种哈西奈德及其衍生物的制备方法
CN108395465B (zh) * 2018-05-10 2019-07-30 浙江仙居仙乐药业有限公司 一种地塞米松环氧水解物的合成方法
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
RS65598B1 (sr) 2021-07-09 2024-06-28 Astrazeneca Pharmaceuticals Lp Sastavi, postupci i sistemi za isporuku aerosolnog leka
EP4452230A1 (en) 2021-12-20 2024-10-30 Astrazeneca AB Compositions, methods and systems for aerosol drug delivery
EP4566595A1 (en) 2023-12-07 2025-06-11 Bernhard Roth Combination preparation for the treatment of acute and chronic rhinosinusitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1059906B (de) * 1954-10-05 1959-06-25 Scherico Ltd Verfahren zur Herstellung von 1, 4-Pregnadienen
US3557158A (en) * 1962-01-22 1971-01-19 Upjohn Co 6alpha-fluoro-16-methyl - 4 - pregnene 3,20-diones and intermediates produced in the synthesis thereof
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
IT1061787B (it) * 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
US3784692A (en) * 1967-06-16 1974-01-08 Warner Lambert Co 17-propionate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US3980778A (en) * 1973-10-25 1976-09-14 The Upjohn Company Anti-inflammatory steroid
NL7502252A (nl) * 1974-02-27 1975-08-29 Pierrel Spa Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden.
GB1505701A (en) * 1975-06-14 1978-03-30 Pierrel Spa 2-chloro-6beta-fluoropregnanes
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids

Also Published As

Publication number Publication date
ZA82566B (en) 1982-12-29
PH19733A (en) 1986-06-17
IE52576B1 (en) 1987-12-23
NO157020C (no) 1988-01-06
OA07116A (fr) 1984-03-31
AU549102B2 (en) 1986-01-16
NL930095I2 (nl) 1994-12-01
NZ199600A (en) 1984-09-28
IL64885A0 (en) 1982-03-31
BG60799B2 (bg) 1996-03-29
EP0057401A1 (en) 1982-08-11
PT74357B (en) 1984-05-30
PT74357A (en) 1982-02-01
FI78111B (fi) 1989-02-28
NO157020B (no) 1987-09-28
NO1994018I1 (no) 1994-10-07
ATE8790T1 (de) 1984-08-15
FI820280L (fi) 1982-08-03
IL64885A (en) 1985-05-31
DK39082A (da) 1982-08-03
DK162770C (da) 1992-04-27
HK68487A (en) 1987-10-02
NL930095I1 (nl) 1993-10-01
KE3694A (en) 1987-03-13
NO820263L (no) 1982-08-03
DK162770B (da) 1991-12-09
CA1177822A (en) 1984-11-13
KR890000761B1 (ko) 1989-04-05
FI78111C (fi) 1989-06-12
US4472393A (en) 1984-09-18
HU188769B (en) 1986-05-28
JPS57146800A (en) 1982-09-10
AU7991882A (en) 1982-08-12
MX9203403A (es) 1992-07-01
JPS6360036B2 (enExample) 1988-11-22
KR830009138A (ko) 1983-12-17
IE820207L (en) 1982-08-02
EP0057401B1 (en) 1984-08-01
CY1359A (en) 1987-08-07

Similar Documents

Publication Publication Date Title
DE3260474D1 (en) Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
JPS54132566A (en) Guanidine derivative*its manufacture and secretion controlling pharmaceutical composition containing it
DE2962418D1 (en) Pharmaceutical composition comprising 3-oxo-2,3-dihydro-(1)-benzothiophene-2-spirocyclopropane and this compound for use in the prophylaxis or treatment of cardiovascular disturbance
DE2963572D1 (en) Mercapto-imidazole derivatives, their preparation, mercapto-imidazole derivatives for the treatment of inflammatory diseases and their pharmaceutical compositions
JPS5540670A (en) Novel pyrimidone derivative*its manufacture and its medical composition
DE3261760D1 (en) Pharmaceutical compositions for the treatment of skin
IL67940A0 (en) 2,3-diaryl-5-halo-thiophenes,their preparation and pharmaceutical compositions containing them
ZA792043B (en) Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines,process for the preparation thereof and pharmaceutical compositions containing them
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
ZA929879B (en) Compositions for the treatment of mammalian diseases.
IL56442A0 (en) Pharmaceutical compositions comprising an adipic aced ester derivative and their use in the prophylaxis and/or treatment of certain desease
JPS5533484A (en) 1*33benzoxazinee2*44dione derivative*its manufacture and medical composition
PH17582A (en) Pharmaceutical compositions for the treatment of diabetes
IL66190A0 (en) Esters of 2-thenoylmercapto propionylglycerine with substituted hydroxybenzenes,process for their preparation and pharmaceutical compositions containing them
IL82376A (en) Pharmaceutical composition for the treatment of inflammatory conditions
IL59283A (en) Laevorotatory basic derivative of 9,10-ethanoanthracene,its production and pharmaceutical compositions containing it
IL89472A0 (en) Pharmaceutical compositions containing sufotidine for the treatment of inflammatory conditions

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: MOMETASON-17-(2-FUROAT); REGISTRATION NO/DATE: 27209.00.00 - 27209.00.02; 19921116

Spc suppl protection certif: 193 75 058

Filing date: 19930624

V457 Spc granted

Free format text: PRODUCT NAME: MOMETASON-17-(2-FUROAT); REGISTRATION NO/DATE: 27209.00.00 - 27209.00.02; 19921116

Spc suppl protection certif: 193 75 058

Filing date: 19930624

V464 Spc expired

Free format text: PRODUCT NAME: MOMETASON-17-(2-FUROAT); REGISTRATION NO/DATE: 27209.00.00 - 27209.00.02; 19921116

Spc suppl protection certif: 193 75 058

Filing date: 19930624